Literature DB >> 9888467

DNA alkylation and interstrand cross-linking by treosulfan.

J A Hartley1, C C O'Hare, J Baumgart.   

Abstract

The anti-tumour drug treosulfan (L-threitol 1,4-bismethanesulphonate, Ovastat) is a prodrug for epoxy compounds by converting non-enzymatically to L-diepoxybutane via the corresponding monoepoxide under physiological conditions. The present study supports the hypothesis that this conversion of treosulfan is required for cytotoxicity in vitro. DNA alkylation and interstrand cross-linking of plasmid DNA is observed after treosulfan treatment, but this is again produced via the epoxide species. Alkylation occurs at guanine bases with a sequence selectivity similar to other alkylating agents such as the nitrogen mustards. In treosulfan-treated K562 cells, cross-links form slowly, reaching a peak at approximately 24 h. Incubation of K562 cells with preformed epoxides shows faster and more efficient DNA cross-linking.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888467      PMCID: PMC2362201          DOI: 10.1038/sj.bjc.6690043

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Treosulfan and gemcitabine.

Authors:  Ian A Cree; Michael H Neale; Uwe Reinhold; Christian M Kurbacher
Journal:  J Cancer Res Clin Oncol       Date:  2005-02-08       Impact factor: 4.553

2.  Structure of the 1,4-Bis(2'-deoxyadenosin-N(6)-yl)-2S,3S-butanediol intrastrand DNA cross-link arising from butadiene diepoxide in the human N-ras codon 61 sequence.

Authors:  Wen Xu; W Keither Merritt; Lubomir V Nechev; Thomas M Harris; Constance M Harris; R Stephen Lloyd; Michael P Stone
Journal:  Chem Res Toxicol       Date:  2007-01-27       Impact factor: 3.739

3.  The 5'-GNC site for DNA interstrand cross-linking is conserved for diepoxybutane stereoisomers.

Authors:  Julie T Millard; Trevor C Hanly; Kris Murphy; Natalia Tretyakova
Journal:  Chem Res Toxicol       Date:  2006-01       Impact factor: 3.739

4.  Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.

Authors:  Belén P Solans; Robert Chiesa; Bilyana Doncheva; Helen Prunty; Paul Veys; Iñaki F Trocóniz; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

5.  Loss of Cohesin Subunit Rec8 Switches Rad51 Mediator Dependence in Resistance to Formaldehyde Toxicity in Ustilago maydis.

Authors:  Jeanette H Sutherland; William K Holloman
Journal:  Genetics       Date:  2018-08-06       Impact factor: 4.562

6.  Bifunctional electrophiles cross-link thioredoxins with redox relay partners in cells.

Authors:  Matthew R Naticchia; Haley A Brown; Francisco J Garcia; Andrew M Lamade; Samantha L Justice; Rachelle P Herrin; Kevin A Morano; James D West
Journal:  Chem Res Toxicol       Date:  2013-03-04       Impact factor: 3.739

7.  Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation.

Authors:  Mats Remberger; Johan Törlen; Ibrahim El Serafi; Karin Garming-Legert; Andreas Björklund; Per Ljungman; Mikael Sundin; Moustapha Hassan; Jonas Mattsson
Journal:  Int J Hematol       Date:  2017-08-28       Impact factor: 2.490

8.  Characterization of aziridinylbenzoquinone DNA cross-links by liquid chromatography-infrared multiphoton dissociation-mass spectrometry.

Authors:  Sarah E Pierce; Lynn J Guziec; Frank S Guziec; Jennifer S Brodbelt
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

9.  Polymerase bypass of N7-guanine monoadducts of cisplatin, diepoxybutane, and epichlorohydrin.

Authors:  Jiayu Ye; Caitlin R Farrington; Julie T Millard
Journal:  Mutat Res       Date:  2018-03-20       Impact factor: 2.433

10.  Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  John E Levine; Joseph H Antin; Carl E Allen; Lauri M Burroughs; Kenneth R Cooke; Steven Devine; Helen Heslop; Ryotaro Nakamura; Julie An Talano; Gregory Yanik; Nancy DiFronzo
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-05       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.